Reviewer's report

Title: Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Version: 3 Date: 2 October 2012

Reviewer: Fabrizio Gardoni

Reviewer's report:

The review by Daneault and co-workers focuses on a main issue in the field of Parkinson's Disease, that is the onset and management of drug (L-DOPA) induced dyskinesia. The authors aim to provide a complete review of molecular mechanisms of dyskinesia, as well as to present a possible new way to view its management.

Major Compulsory Revisions:
I think that several points need to be improved.

The authors attempt to cover all main issues in the field ranging from current treatments to molecular mechanisms associated with the onset of dyskinesia, from clinical practice to identification of new algorithms. I think that a review more focused on very few of these items would be more helpful; in particular, the first part on current and future treatments could be dramatically reduced, because already addressed in more details in many other reviews in the last few years. On the other hand, to expand the second part of the review concerning the impact of better management of dyskinesias on the healthcare system and the theory behind the proposed approach would be important.

Minor Essential Revisions
The section about glutamate receptors, A2A is somehow confused, interrupted by other paragraphs, and not fluent. This part of the review really needs extensive revision, or improved or omitted. Moreover, also the section related to new possible treatments is very short and incomplete, maybe it is much better or to remove or to expand it.

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.